For decades, European governments have framed health spending as a necessary burden a cost to be contained, a line item to be squeezed. Budget negotiations have traditionally pitted healthcare against infrastructure, defence, and education, with the implicit assumption that money spent on hospitals and medicines is money diverted from “productive” sectors of the economy. That mindset is now being decisively overturned. Across Brussels, national capitals, and the boardrooms of Europe’s largest pharmaceutical companies, a new consensus is emerging: healthcare is not a drain on public finances but one of the continent’s most powerful engines of economic growth, innovation, and strategic resilience. The European Union is in the midst of a fundamental strategic pivot, reimagining health as an investment rather than a cost and backing that vision with unprecedented financial commitments. From the €10 billion BioTechEU initiative to the first major reform of EU pharmaceutical legislation in two decades, the bloc is betting that healthier populations, cutting-edge life sciences, and robust health security are not merely compatible with economic competitiveness but essential to it. Understanding this shift is not an abstract policy exercise; it is a matter of direct financial relevance for every European taxpayer, investor, healthcare professional, and patient. The way Europe spends on health today will determine the continent’s productivity, fiscal sustainability, and global standing for a generation.
The intellectual foundation for this transformation rests on a growing body of empirical evidence that challenges conventional fiscal orthodoxy. Studies examining the economic impact of government spending across European economies have consistently found that health expenditure generates remarkably high returns. Research covering 25 EU countries from 1995 to 2010 calculated fiscal multipliers the economic return for each euro of government spending ranging from a deeply negative 9.8 for defence to an extraordinary 4.3 for health, meaning that every euro invested in healthcare generates approximately €4.30 in broader economic benefits. More recent analyses have reinforced this finding, with evidence suggesting that for every €1 Europe invests in health, it receives more than double back in economic benefits in addition to direct health improvements. The EU Health Coalition has gone further, asserting that investments in the health sector deliver the greatest financial value to Europe’s productivity and competitiveness compared with investments in any other sector. The evaluation of Horizon 2020, the EU’s flagship research and innovation programme, demonstrated that every euro invested in EU research, development, and innovation yielded significant benefits, contributing directly to GDP growth and societal gains. These are not theoretical projections but measured outcomes, and they have fundamentally altered how policymakers think about health budgets.
The sheer scale of the health and life sciences sector as an economic force is itself compelling. According to the European Commission’s Joint Research Centre, life sciences sectors account for 9.4% of EU GDP and employ 29 million people, making them one of the largest and most productive components of the European economy. These sectors have driven economic growth in recent years, with increasing GDP contributions and job creation in productive areas, offering high growth potential and innovation capacity to address the continent’s most pressing challenges. Biotechnology alone, a subset of the broader life sciences landscape, has been growing at twice the rate of the overall EU economy over the past decade, creating more than 900,000 jobs and contributing nearly €40 billion to European output. The medical devices industry encompasses over 38,000 companies 90% of them small and medium-sized enterprises employing nearly one million people and generating a market value of approximately €170 billion. These are not marginal sectors; they are central pillars of European economic activity, and investing in them yields returns that ripple through the entire economy.
Perhaps the most urgent argument for treating health as an investment lies in the relationship between population health and workforce productivity. Europe faces a demographic crisis: a shrinking working-age population combined with rising rates of chronic disease and mental illness. Cardiovascular diseases alone remain the leading cause of death in the EU, accounting for over 1.7 million deaths and costing the economy up to €282 billion annually.
Cancer is set to overtake cardiovascular conditions as the leading cause of death in the EU by 2035, while globally new cases are projected to reach 35 million by 2050 a 77% increase from 2022. The Draghi Report on European competitiveness, though criticised for largely omitting health as a strategic factor, nonetheless acknowledged that illness is a major reason for workforce exit, with health shocks in middle age markedly increasing the probability of leaving the labour force. Poor mental health, a growing problem across the continent, affects workforce participation across the life course and is particularly damaging in regions with few alternative job opportunities. When workers are healthy, they are more productive, take fewer sick days, and remain in the workforce longer each of which directly boosts GDP and reduces welfare dependency. Conversely, cutting health spending to save money in the short term leads to higher healthcare costs later, as untreated conditions worsen and require more expensive interventions, while also reducing the pool of available labour.
The new EU strategy is translating this evidence into concrete financial commitments. At the heart of the shift is the Biotech Act, proposed in December 2025 as part of a broader package of health sector measures. The Act is designed to turn Europe into a “biotech powerhouse,” addressing critical gaps in funding, regulatory bottlenecks, and innovation barriers that have seen the EU’s global share of commercial clinical trials fall from 22% to just 12% over the past decade, while its share of global venture capital investment in health biotech languishes at only 7% compared to 14% in China and 63% in the United States.
The flagship initiative under the Biotech Act is BioTechEU, a collaboration between the European Commission and the European Investment Bank Group to mobilise €10 billion in investment into the biotech and life sciences sector over 2026–2027. The initiative builds on the EIB Group’s existing life sciences venture debt portfolio of approximately €3.5 billion across 135 projects and is designed to address the EU’s investment gap by mobilising public-private capital into promising new health solutions, from AI-driven cardiac sensors to mRNA therapies and gene therapies. As EU Commissioner for Health and Animal Welfare Olivér Várhelyi stated, “Under-investment is a major stumbling block for Europe’s biotech companies and a serious obstacle for our innovative start-ups”. The BioTechEU project aims to reverse that trend, providing the financial support needed to ensure that breakthroughs made in Europe can scale and thrive in Europe.
Alongside the Biotech Act, the EU has completed the first major reform of pharmaceutical legislation in 20 years, finalised in December 2025. The new framework, which builds directly on the Draghi Report’s warnings about Europe’s lagging pharmaceutical innovation, is designed to strengthen competitiveness while ensuring patient access. The agreement introduces stronger incentives for innovation in rare diseases, benefiting the 36 million Europeans living with rare conditions, and makes Europe the first region in the world to put in place market incentives for the development of new antibiotics a direct response to the silent pandemic of antimicrobial resistance. The reforms also tackle medicine shortages and enhance Europe’s strategic autonomy in public health and pharmaceuticals, addressing structural vulnerabilities that were exposed during the COVID-19 pandemic and subsequent geopolitical shocks. The Critical Medicines Act, proposed separately, aims to strengthen pharmaceutical supply chains, boost manufacturing capacity within the EU, and ensure equitable access to medicines of critical and common interest across the Union.
The budgetary commitments are equally significant. The European Parliament’s Public Health Committee (SANT) has approved a package of amendments to the 2026 EU budget that significantly increases resources for health. The amendments include substantial increases for the Horizon Europe health cluster, with particular attention to rare diseases, cardiovascular and oncological diseases, mental health, paediatric health, and the fight against antimicrobial resistance. The EU4Health programme, the largest health programme in EU history, received a proposed 17.6% increase for 2026, though the Parliament has stressed that this remains below the levels agreed in the Multiannual Financial Framework prior to the mid-term review. Additional funding of up to €300 million has been proposed for human and animal health protection, exceeding the Council’s allocation of €243 million. These increases reflect a clear political signal: health must remain a strategic priority for the EU, with funding to match population needs
The economic dividends of this investment-led approach are already being quantified. A study by Frontier Economics, published by the European Federation of Pharmaceutical Industries and Associations (EFPIA), found that industry-sponsored clinical trials already generate €35.7 billion in economic value each year across the European Economic Area, supporting 165,000 jobs including over 45,000 clinical research positions. Meeting the new EU target of an 11% increase in clinical trials designed to reverse the decade-long decline would deliver an additional €4 billion annually to EU healthcare systems and the wider economy, create 18,000 new jobs, and prevent 3 million sick days. A more ambitious scenario, regaining Europe’s “lost trials” that have moved out of the region since 2013, would require a 25% increase in trial activity, delivering €8.9 billion in additional Gross Value Added and 79,000 more clinical trial places. A third scenario, matching the global leaders—the US and China would unlock up to €17.9 billion for Europe’s economy and 158,000 additional trial places. These figures demonstrate that treating healthcare as an investment is not a matter of altruism but of hard-headed economic calculation.
The connection between this strategic shift and personal finance is direct and multifaceted. For the individual taxpayer, the recognition that health spending generates high economic returns means that funds allocated to healthcare are not wasted but rather contribute to GDP growth, job creation, and fiscal sustainability. For workers, the focus on workforce health as a productivity driver translates into better access to preventive care, shorter waiting times, and reduced risk of illness-related job loss. For investors, the €10 billion BioTechEU initiative and the broader pharmaceutical reforms signal that European life sciences are a growth sector attracting significant public and private capital. The EU is actively working to close the gap with the US and China in biotech investment, creating opportunities for venture capital, private equity, and public markets. For patients, the new pharmaceutical legislation promises faster access to innovative medicines, stronger incentives for rare disease treatments, and enhanced security against medicine shortages. For employers, healthier workforces mean lower absenteeism, higher productivity, and reduced healthcare costs. For the self-employed and gig workers, who lack the buffer of employer-sponsored health benefits, the EU’s investment in resilient health systems provides a critical safety net.
The strategic shift also has profound implications for Europe’s competitive position in the global economy. The United States, under the Trump administration’s aggressive industrial policies, has been actively attracting pharmaceutical and biotech companies with tax incentives and regulatory advantages. China has rapidly expanded its share of global clinical trials from 8% to 18% over the past decade, while Europe’s share has fallen from 22% to 12%. The EU’s new strategy is a direct response to this competitive pressure, aiming to make Europe the most attractive place in the world for life sciences by 2030. The Biotech Act, the pharmaceutical reforms, and the increased budget for EU4Health are all designed to reverse the brain drain of talent and capital, ensuring that the next generation of breakthrough therapies from gene editing to personalised medicine are developed and manufactured in Europe rather than elsewhere. This matters for European economic sovereignty because the life sciences sector is not only a major employer but also a source of high-value exports, technological leadership, and strategic resilience.
The evidence is clear: healthcare is not a cost to be minimised but an investment with demonstrable economic returns. The EU’s new strategy, backed by €10 billion in biotech investment, the first major pharmaceutical reform in two decades, and significant budget increases for health programmes, represents a fundamental reorientation of European economic policy. The old paradigm treating health spending as a burden on competitiveness has been replaced by a new understanding: health is the foundation of a productive workforce, a driver of innovation, and a pillar of strategic autonomy. The choice for Europe, as articulated by the Euronews debate on the value of investing in healthcare, is stark: treat health as a cost and pay the price later, or treat it as an investment and unlock decades of growth, stability, and wellbeing. The EU has made its choice. The question now is how quickly the benefits of this investment-led approach will flow through to citizens, patients, and the broader economy—and whether other regions will follow Europe’s lead in recognising that health is not a drain on prosperity but the very engine of it.